MX2014014765A - Inhibidores macrociclicos de virus flaviviridae. - Google Patents

Inhibidores macrociclicos de virus flaviviridae.

Info

Publication number
MX2014014765A
MX2014014765A MX2014014765A MX2014014765A MX2014014765A MX 2014014765 A MX2014014765 A MX 2014014765A MX 2014014765 A MX2014014765 A MX 2014014765A MX 2014014765 A MX2014014765 A MX 2014014765A MX 2014014765 A MX2014014765 A MX 2014014765A
Authority
MX
Mexico
Prior art keywords
flaviviridae viruses
macrocyclic inhibitors
compounds
macrocyclic
inhibitors
Prior art date
Application number
MX2014014765A
Other languages
English (en)
Other versions
MX358372B (es
Inventor
Richard Mackman
Linos Lazarides
Victoria Alexandra Steadman
Caroline Aciro
David Kenneth Dean
Andrew John Keats
Karine G Poullennec
Dustin Scott Siegel
Adam James Schrier
Adrian John Highton
Jean Yves Chiva
Gregory Watt
Petr Jansa
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2014014765A publication Critical patent/MX2014014765A/es
Publication of MX358372B publication Critical patent/MX358372B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)

Abstract

Se proporcionan compuestos de la Fórmula I: (ver Fórmula) y sales y ésteres farmacéuticamente aceptables de los mismos. Los compuestos, composiciones, y métodos proporcionados son útiles para el tratamiento de infecciones por virus, particularmente infecciones por hepatitis C.
MX2014014765A 2012-06-08 2013-06-07 Inhibidores macrociclicos de virus flaviviridae. MX358372B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657562P 2012-06-08 2012-06-08
PCT/US2013/044812 WO2013185093A1 (en) 2012-06-08 2013-06-07 Macrocyclic inhibitors of flaviviridae viruses

Publications (2)

Publication Number Publication Date
MX2014014765A true MX2014014765A (es) 2015-04-13
MX358372B MX358372B (es) 2018-08-16

Family

ID=48626704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014765A MX358372B (es) 2012-06-08 2013-06-07 Inhibidores macrociclicos de virus flaviviridae.

Country Status (34)

Country Link
US (4) US9062092B2 (es)
EP (2) EP2861601B1 (es)
JP (1) JP6273268B2 (es)
KR (1) KR102185152B1 (es)
CN (1) CN104781261B (es)
AP (1) AP2015008189A0 (es)
AR (1) AR091279A1 (es)
AU (1) AU2013270670B2 (es)
BR (1) BR112014030639A2 (es)
CA (1) CA2875690C (es)
CL (1) CL2014003337A1 (es)
CR (1) CR20150018A (es)
EA (1) EA027134B1 (es)
EC (1) ECSP15000435A (es)
ES (2) ES2672480T3 (es)
HK (2) HK1209731A1 (es)
IL (1) IL236007B (es)
IN (1) IN2014MN02657A (es)
MA (1) MA37712B1 (es)
MD (1) MD20140135A2 (es)
MX (1) MX358372B (es)
NO (1) NO2885641T3 (es)
NZ (1) NZ703062A (es)
PE (1) PE20150862A1 (es)
PH (1) PH12014502739B1 (es)
PL (1) PL2861601T3 (es)
PT (1) PT2861601T (es)
SG (2) SG11201408064PA (es)
SI (1) SI2861601T1 (es)
TW (1) TWI616448B (es)
UA (1) UA115664C2 (es)
UY (1) UY34851A (es)
WO (1) WO2013185093A1 (es)
ZA (1) ZA201409215B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
NZ724503A (en) * 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
MX2014014768A (es) 2012-06-08 2015-05-11 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae.
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (zh) 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
EP3092229B1 (en) 2014-01-06 2018-03-28 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
CU20170115A7 (es) 2015-03-04 2018-03-13 Gilead Sciences Inc Compuestos moduladores de receptor de tipo toll
AU2016312508A1 (en) 2015-08-26 2018-02-15 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
EP3355930A4 (en) 2015-10-01 2019-03-06 Warp Drive Bio, Inc. METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
US11738013B2 (en) 2016-05-27 2023-08-29 Gilead Sciences, Inc. Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
DK3526323T3 (da) 2016-10-14 2023-06-26 Prec Biosciences Inc Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet
WO2018136559A1 (en) * 2017-01-17 2018-07-26 The Regents Of The University Of California Methods for treating flaviviruses and zika infections
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2018232174A2 (en) * 2017-06-16 2018-12-20 Avalon Flaviviral Therapeutics (Hk) Limited Compositions and methods for treating flavivirus infections
WO2019040102A1 (en) 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
GB2590198B (en) 2017-12-07 2022-02-23 Univ Emory N4-hydroxycytidine derivatives and anti-viral uses related thereto
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3752501B1 (en) 2018-02-13 2023-04-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020010200A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
JP7199502B2 (ja) 2018-07-06 2023-01-05 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
CR20210013A (es) 2018-07-13 2021-02-26 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
AU2019401466A1 (en) * 2018-12-21 2021-07-01 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4037708A1 (en) 2019-09-30 2022-08-10 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
EP4144353A1 (en) * 2020-04-30 2023-03-08 FUJIFILM Toyama Chemical Co., Ltd. Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
MX2023001507A (es) 2020-08-07 2023-03-06 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
GB202207348D0 (en) 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62193147A (ja) 1986-02-19 1987-08-25 Toshiba Corp 半導体装置の製造方法
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
JP2003510360A (ja) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US20050159345A1 (en) * 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
CN101602741A (zh) 2004-06-30 2009-12-16 先灵公司 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺
MX2007015909A (es) 2005-06-16 2008-03-06 Cv Therapeutics Inc Profarmacos de antagonistas del receptor de adenosina a2b.
MX2007016068A (es) 2005-06-17 2008-03-10 Novartis Ag Uso de sanglifehrina en hcv.
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US20100285056A1 (en) 2008-01-09 2010-11-11 Konkuk University Industrial Cooperation Corp. Baculovirus-Based Vaccines
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
ES2429013T3 (es) * 2008-12-23 2013-11-12 Janssen Pharmaceuticals, Inc. Procedimientos e intermedios para la preparación de un inhibidor macrocíclico de la proteasa de VHC
TWI491609B (zh) 2010-01-15 2015-07-11 Gilead Sciences Inc 黃熱病毒科（Ｆｌａｖｉｖｉｒｉｄａｅ）病毒之抑制劑類
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
US20130178413A1 (en) 2010-09-21 2013-07-11 John A. McCauley Hcv ns3 protease inhibitors
AR084217A1 (es) * 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
NZ701721A (en) 2012-06-08 2016-03-31 Glenmark Pharmaceuticals Sa Amides of 2-amino-4-arylthiazole compounds and their salts
NZ724503A (en) 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
MX2014014768A (es) 2012-06-08 2015-05-11 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae.
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae

Also Published As

Publication number Publication date
PH12014502739A1 (en) 2015-02-02
EP3392253A1 (en) 2018-10-24
PH12014502739B1 (en) 2015-02-02
IN2014MN02657A (es) 2015-08-28
JP2015525221A (ja) 2015-09-03
ECSP15000435A (es) 2015-12-31
CL2014003337A1 (es) 2015-07-10
TWI616448B (zh) 2018-03-01
CA2875690C (en) 2021-09-07
HK1212349A1 (en) 2016-06-10
TW201410680A (zh) 2014-03-16
US20150361132A1 (en) 2015-12-17
AR091279A1 (es) 2015-01-21
IL236007B (en) 2018-01-31
US9642889B2 (en) 2017-05-09
JP6273268B2 (ja) 2018-01-31
AU2013270670A1 (en) 2015-01-22
NO2885641T3 (es) 2018-03-31
ZA201409215B (en) 2016-01-27
MD20140135A2 (ro) 2015-05-31
CN104781261A (zh) 2015-07-15
EP2861601B1 (en) 2018-02-07
EP2861601A1 (en) 2015-04-22
AU2013270670B2 (en) 2017-10-19
MA37712B1 (fr) 2019-03-29
US10472392B2 (en) 2019-11-12
US20130344030A1 (en) 2013-12-26
BR112014030639A2 (pt) 2017-06-27
CN104781261B (zh) 2017-08-25
EA201492188A1 (ru) 2015-09-30
UY34851A (es) 2013-12-31
MX358372B (es) 2018-08-16
EP3392253B1 (en) 2021-08-25
UA115664C2 (uk) 2017-12-11
ES2894269T3 (es) 2022-02-14
ES2672480T3 (es) 2018-06-14
SI2861601T1 (en) 2018-07-31
WO2013185093A1 (en) 2013-12-12
MA37712A2 (fr) 2016-06-30
PE20150862A1 (es) 2015-06-17
US20160220633A1 (en) 2016-08-04
PT2861601T (pt) 2018-06-12
HK1209731A1 (en) 2016-04-08
CR20150018A (es) 2015-06-04
KR102185152B1 (ko) 2020-12-01
PL2861601T3 (pl) 2018-08-31
CA2875690A1 (en) 2013-12-12
SG10201703969PA (en) 2017-06-29
EA027134B1 (ru) 2017-06-30
SG11201408064PA (en) 2015-01-29
US20170190734A1 (en) 2017-07-06
AP2015008189A0 (en) 2015-01-31
NZ703062A (en) 2016-09-30
US9062092B2 (en) 2015-06-23
IL236007A0 (en) 2015-02-01
KR20150040267A (ko) 2015-04-14

Similar Documents

Publication Publication Date Title
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
HK1166788A1 (es)
IN2012DN01855A (es)
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
UA107801C2 (en) Derivatives of thiophene-2-carboxylic acid inhibitors viruses flaviviridae

Legal Events

Date Code Title Description
FG Grant or registration